Opportunity To Co-Sponsor Events With the Office of Research Integrity

Issuing agencies

Abstract

The Office of Research Integrity (ORI) announces an ongoing opportunity for non-federal public and private sector entities to co- sponsor conferences, workshops, symposia, meetings, roundtables, or other similar events (collectively, "Events") with ORI. ORI co- sponsors a limited number of Events with non-federal entities each year. Potential co-sponsors must have demonstrated interest and experience in the responsible conduct of research or handling allegations of research misconduct and must be willing to substantively contribute to the co-sponsored Event. This notice supersedes ORI's October 21, 2022, co-sponsorship opportunity notice at 87 FR 64067.

Full Text

<html>
<head>
<title>Federal Register, Volume 91 Issue 178 (Wednesday, September 16, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 178 (Wednesday, September 16, 2026)]
[Notices]
[Page 58687]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-18987]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


Opportunity To Co-Sponsor Events With the Office of Research 
Integrity

AGENCY: Office of Research Integrity, Office of the Secretary, 
Department of Health and Human Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Office of Research Integrity (ORI) announces an ongoing 
opportunity for non-federal public and private sector entities to co-
sponsor conferences, workshops, symposia, meetings, roundtables, or 
other similar events (collectively, ``Events'') with ORI. ORI co-
sponsors a limited number of Events with non-federal entities each 
year. Potential co-sponsors must have demonstrated interest and 
experience in the responsible conduct of research or handling 
allegations of research misconduct and must be willing to substantively 
contribute to the co-sponsored Event. This notice supersedes ORI's 
October 21, 2022, co-sponsorship opportunity notice at 87 FR 64067.

DATES: Expressions of interest for co-sponsoring an Event with ORI may 
be submitted starting October 1, 2026, and will be reviewed on an 
ongoing basis.

ADDRESSES: Expressions of interest for co-sponsoring an Event with ORI 
should be sent by email to <a href="/cdn-cgi/l/email-protection#baf5e8f3f9d5d7d7c9faf2f2e994fdf5ec"><span class="__cf_email__" data-cfemail="8ac5d8c3c9e5e7e7f9cac2c2d9a4cdc5dc">[email&#160;protected]</span></a> with ``Co-sponsoring an 
Event with ORI'' in the subject field.

FOR FURTHER INFORMATION CONTACT: 
    Chenelle Johnson, Program Analyst, U.S. Department of Health and 
Human Services (HHS) at (240) 268-0775
    Mia Brown, Public Health Analyst, U.S. Department of Health and 
Human Services (HHS) at (240) 453-8265, <a href="/cdn-cgi/l/email-protection#b1fee3f8f2dedcdcc2f1f9f9e29ff6fee7"><span class="__cf_email__" data-cfemail="5b14091218343636281b131308751c140d">[email&#160;protected]</span></a> .

SUPPLEMENTARY INFORMATION: 
    Background: ORI oversees and directs U.S. Public Health Service 
(PHS) research integrity activities on behalf of the Secretary of 
Health and Human Services, except for the regulatory research integrity 
activities of the Food and Drug Administration. ORI is a program office 
within the U.S. Department of Health and Human Services (HHS) Office of 
the Assistant Secretary for Health in the Office of the Secretary.
    Core to ORI's mission are education activities for PHS-funded 
research institutions to teach the responsible conduct of research, 
promote research integrity, prevent research misconduct, and enable 
such institutions to respond effectively to allegations of research 
misconduct. (65 FR 30600, 30601 [May 12, 2000]). Co-sponsored Events 
contribute to this mission by providing education, training, and/or the 
opportunity to discuss topics such as handling allegations of research 
misconduct and fostering research integrity, the responsible conduct of 
research, and gold standard research practices. Gold standard research 
exemplifies the highest levels of scientific rigor, transparency, 
reproducibility, and adherence to ethical standards. Co-sponsored 
Events typically accept between 20 and 150 attendees and convene for 
one to three days.
    Co-sponsors will work with ORI staff to jointly develop an Event. 
Both ORI and co-sponsors must contribute substantively to the 
development of the Event. Co-sponsors may charge registration fees but 
only at levels necessary to recover Event-related expenses. Co-sponsors 
are also solely responsible for collecting and handling any 
registration fees.
    Eligibility for Co-Sponsorship: Potential co-sponsors must:
    <bullet> Have demonstrated interest and experience in fostering the 
responsible conduct of research or handling allegations of research 
misconduct.
    <bullet> Substantively contribute to the content of the co-
sponsored Event beyond funding, logistical services, or other material 
support.
    Expression of Interest in Co-Sponsorship: An entity may submit an 
expression of interest individually or jointly with other entities, 
describing their relative contributions. Please note that ORI may hold 
exploratory discussions with potential co-sponsors after initial review 
of submissions. Entities interested in co-sponsoring an Event with ORI 
should submit a one- to two-page, single-spaced document in at least 
11-point font that includes the following:
    1. Contact information for the entity's representative(s), 
including full name, role, email address, and phone number.
    2. A brief summary (one to two paragraphs) detailing why ORI should 
select the entity, including demonstrated interest and experience in 
the responsible conduct of research or handling allegations of research 
misconduct.
    3. A bullet outline addressing the eight topics listed below 
(roughly one paragraph each):
    a. The entity's demonstration of leadership and management of 
matters involving research integrity.
    b. The entity's prior experience and current readiness to undertake 
the responsibilities of co-sponsoring an Event with ORI.
    c. The type of Event(s) that the entity is interested in co-
sponsoring with ORI.
    d. The entity must be willing to substantively contribute to the 
co-sponsored Event.
    e. Facilities available for the Event(s), including the distance 
from the facilities to a major airport.
    f. Any current constraints with respect to dates or facilities, and 
a suggested time frame of dates (at minimum, month(s) and year for the 
Event).
    g. Whether the entity has co-sponsored an Event with ORI in the 
past 36 months.
    h. Whether the entity has any active research misconduct 
proceedings (regardless of status) of which ORI is unaware.
    Evaluation Criteria: After engaging in exploratory discussions with 
potential co-sponsors who respond to this notice, HHS will apply the 
following five considerations, as appropriate and relevant, to select 
the co-sponsor(s):
    1. Qualifications and capability to fulfill co-sponsorship 
responsibilities.
    2. Suitability of the location of the proposed Event in terms of 
the overall geographical distribution of recent or planned ORI Events.
    3. Potential for the Event to engage an adequate number of 
attendees.
    4. Availability and description of facilities needed to support the 
Event.
    5. Availability of administrative support for the logistics of 
hosting the Event.
    The duties of the co-sponsor will be outlined in a co-sponsorship 
agreement with ORI that will set forth details of the co-sponsored 
Event, including the requirement that any fees collected by the co-
sponsor shall be limited to the amount necessary to cover the co-
sponsor's Event-related expenses. A co-sponsorship agreement does not 
represent an endorsement by ORI of an individual co-sponsor's policies, 
positions, or activities.

Loc Nguyen-Khoa,
Deputy Director, Office of Research Integrity, Office of the Assistant 
Secretary for Health.
[FR Doc. 2026-18987 Filed 9-15-26; 8:45 am]
BILLING CODE P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>